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Abstract
Background: Postoperative nausea and vomiting (PONV) is one of the most common postoperative complications
of general anesthesia in pediatrics. Aromatherapy has been shown to be effective in treating PONV in adults. Given
the encouraging results of the adult studies, we planned to determine feasibility of doing a large-scale study in the
pediatric population.
Methods: Our group conducted a pilot randomized controlled trial examining the effect of aromatherapy on post-
operative nausea and vomiting in patients 4–16 undergoing ambulatory surgery at a single center. Nausea was
defined as a score of 4/10 on the Baxter Retching Faces Scale (BARF scale). A clinically significant reduction was
defined as a two-point reduction in Nausea. Post operatively children were administered the BARF scale in 15 min
internals until discharge home or until nausea score of 4/10 or greater. Children with nausea were randomized to
saline placebo group or aromatherapy QueaseEase™ (Soothing Scents, Inc, Enterprise, AL: blend of ginger, lavender,
mint and spearmint). Nausea scores were recorded post intervention.
Results: A total of 162 subjects were screened for inclusion in the study. Randomization occurred in 41 subjects of
which 39 were included in the final analysis. For the primary outcome, 14/18 (78 %) of controls reached primary
outcome compared to 19/21 (90 %) in the aromatherapy group (p = 0.39, Eta 0.175). Other outcomes included use
of antiemetic in PACU (control 44 %, aromatherapy 52 % P = 0.75, Eta 0.08), emesis (Control 11 %, 9 %
aromatherapy, P = 0.87, Eta = 0.03). There was a statistically significant difference in whether subjects continued to
use the intervention (control 28 %, aromatherapy 66 %, p-value 0.048, Eta 0.33).
Conclusion: Aromatherapy had a small non-significant effect size in treating postoperative nausea and vomiting
compared with control. A large-scale randomized control trial would not be feasible at our institution and would
be of doubtful utility.
Trial registration: ClinicalTrials.gov NCT02663154.
Keywords: MeSH postoperative nausea and vomiting, Aromatherapy, Ambulatory surgical procedures, Pediatrics,
Nausea, Antiemetics, Complementary therapies
Background
Postoperative nausea and vomiting (PONV) is one of the
most common postoperative complications of general
anesthesia in pediatrics. Pediatric rates of nausea and
vomiting are approximately double those of adult patients
(approximately 40 %) [1, 2]. PONV is an unpleasant experi-
ence with potential secondary complications such as
wound dehiscence, electrolyte abnormalities and aspiration
pneumonia. PONV can also result in significantly delayed
post anesthetic care unit (PACU) stays, which can lead to
delayed hospital discharge [3]. In a study using a ‘willing-
ness-to-pay technique,’ parents were willing to pay up to
$80 to prevent nausea, suggesting that parents feel PONV
is a significant problem [4].
Aromatherapy has been shown to be effective in treating
PONV in adults [5–7]. Aromatherapy is the use of essen-
tial oils to alleviate emotional or physical discomfort. The
cellular and physiological means by which aromatherapy
acts is poorly understood [8]. Meta-analysis of four previ-
ous studies (215 subjects) failed to show a significant effect
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of isopropyl alcohol compared with standard treatment for
relief of nausea. [8] Peppermint was also examined in this
Cochrane review and there was insufficient quality evi-
dence to show an effect of peppermint-based aromather-
apy. However, this review did not include the largest trial
in adult aromatherapy for PONV. In 2013 Hunt et al.
enrolled 1151 adults in a four armed randomized control
trial for aromatherapy and showed that the blend (ginger,
peppermint, spearmint and cardamom) reduced nausea
compared to saline: 82.4 % reported reduced nausea with
blend compared to control 39.7 % (P < 0.001) [6]. A num-
ber of smaller studies have also shown efficacy of aroma-
therapy in treating adult PONV [5, 7, 9].
QueaseEase™ (Soothing Scents, Inc, Enterprise, AL) is
one of the proprietary blends of aromatherapy that has
been shown to be effective in treating PONV in adults. In
a study of 339 patients, 94 reported nausea and were ran-
domized to aromatherapy or placebo. The intervention re-
sulted in a reduction in mean visual analogue nausea
score of 5.4 pre aromatherapy to 3.4 post aromatherapy
p = 0.01. This difference was significantly greater than
nausea reduction by placebo: 5.6 pre and 4.4 post P = 0.03
[5]. Given the encouraging results of the first adequately
powered adult study, we planned to determine feasibility
of doing a large-scale study in the pediatric population.
Herein we report a pilot randomized control trial to
assess the feasibility of a larger scale randomized clinical
trial. The aim is to identify refinements necessary to the
study protocol, assess costs, and obtain a valid estimate
for power calculations. Hence, to answer in future stud-
ies whether aromatherapy is an effective therapy for the
management of PONV in the pediatric population.
Methods
The study was conducted at the Isaac Walton Killam
(IWK) Health Centre in Halifax, Nova Scotia. After insti-
tutional ethics review, participants were recruited in two
discrete collection periods by three research assistants
(July 14-Sept 23 2014 and March 24-May 19 2015). Inclu-
sion criteria included children aged 4–16, Anesthesia Soci-
ety of America Physical Status I or II (ASA I or II),
absence of neurodevelopmental disorders, and undergoing
elective day surgery. Exclusion criteria included patient or
family refusal, allergy or sensitivity to aromatherapy com-
ponents, inability to smell or failure to meet the inclusion
criteria. Of note, the protocol was modified at the study
mid-point to increase enrollment. Originally, only oto-
laryngology and ophthalmology patients were included,
but this was expanded to the previously described inclu-
sion criteria due to low rates of PONV.
Study intervention
The intervention was a proprietary blend of aromatherapy
essential oils (QueaseEASE™). The mixture included
(Lavandula angustifolia, Mentha Spicata, Mentha xpiper-
ita and Zingiber officinale) in equal proportions and is reg-
istered with Health Canada (Natural Product Number
80036451). The control was with identical housing but con-
tained only saline (Fig. 1).
Measurement tool
BARF scale
The Baxter Retching Faces (BARF) scale is a pictorial
nausea scale of 0–10 with 6 faces. This tool was vali-
dated in the paediatric emergency room, with paediatric
cancer inpatients and in the paediatric postoperative
care unit [10]. This instrument has achieved construct
validity for assessment of severity of paediatric nausea.
The scale also has convergent and discriminatory validity
and can detect changes after therapy. Originally vali-
dated for patients aged 7–18 years old, this scale has
been used in ages as low as 4 [10].
Procedure
A pilot trial designed to accurately replicate future larger
study design was undertaken as follows.
On the day of their surgical procedure, children were
screened using the inclusion and exclusion criteria.
Children whom met the criteria were enrolled after
obtaining informed consent from the parent with assent
from the child. Enrolment took place prior to the start
of the scheduled procedure.
Upon enrollment, charts were reviewed for demo-
graphic data (age, sex, weight), co-morbidities, previous
anesthetics, and previous PONV. Attending anesthesiolo-
gists were not made aware of the subject’s participation in
the study and there were no attempts made to alter stand-
ard anesthetic management. Not standardizing anesthesia
management improves external validity and applicability
to the general pediatric peri-operative population.
Post-operatively subjects went to the first stage post
anesthetic care unit (PACU 1) until they met discharge
criteria. They were then moved to PACU 2 (post recovery)
until discharge home. Upon arrival to PACU 1, the re-
search assistant assessed for nausea using the BARF scale
at 15-min intervals or if the patient or nurse reported nau-
sea. The nurse also independently assessed nausea at 15-
min intervals. If the patient reported a BARF scale of 4 or
greater they were randomized to the intervention aroma-
therapy or a saline inhaler. Randomization was by block 6
design. Concealment was maintained by using sequentially
numbered opaque envelopes containing the identical
appearing intervention and control inhalers (Fig. 1). Upon
the report of nausea, the patient was given the inhaler
with instructions on its use. Specifically, subjects were
asked to take deep regular breaths through their nose with
the inhaler in front of their nose. They were told to do so
as long as they wanted and to repeat as necessary until the
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nausea passed. Based on the preference of the participant,
the inhaler was held by either the participant, a parent, or
the research assistant. BARF scale was re-evaluated after
sufficient exposure (defined as 5 respiratory cycles of nasal
breathing using the inhaler within 30 cm from their
nares). The primary outcome was defined as a 2-
point reduction in the BARF-Scale. A two-point dif-
ference is a one-face difference on the pictorial scale.
This difference would be analogous to a significant
clinical effect in the pain literature and has been used
in the pediatric nausea literature [10]. Additional
BARF scale measurements were collected at 15-min
intervals until the time of discharge.
Statistical analysis
Power consideration
The nature of this study was to select a convenience
sample of 40 patients (20 in each group) to serve as an
estimate for power in a future study. The current litera-
ture does not contain a study similar enough that as-
sumptions for a sample size calculation would be valid.
A sample size of 40 patients is generally sufficient to cre-
ate an accurate estimate of variance in which a future
power calculation could be made.
Analysis
SPSS version 23.0 was used for analysis. Descriptive
statistics were generated and are presented as means
with standard deviation or as percentages. T-tests
and chi-square were used to compare groups on
baseline data including child age, surgical procedure,
previous PONV and co-morbidities. T-tests (or Ana-
lysis of Covariance) were used to examine differences
on primary.
Results
A total of 162 subjects were screened for inclusion in
the study. Of these subjects, 4 surgeries were cancelled,
2 were changed to same day admission, 2 parents with-
drew consent, and 2 patients were excluded retrospect-
ively for ASA status III. The overall rate of nausea as
defined as 4/10 on the BARF nausea scale was 41/152
(27 %). Randomization occurred in 41 subjects of which
2 were excluded post randomization (1 subject in each
arm [1], for failure to meet exposure criteria and [1] for
leaving before assessment (Fig. 2)).
Age, sex, ASA status, total time in operating room,
PONV prophylaxis and pain management were not sig-
nificantly different between intervention and control
groups (Table 1). There were differences in the type of
surgical procedures between groups. The major differ-
ence was a greater portion of patients in the aromather-
apy group had ENT procedures compared with the
control group (81 % versus 44 %) (Table 1). When com-
paring the groups for nausea prophylaxis, 78 % of the
control and 71 % of the aromatherapy group received
Ondansetron and 94 % of control and 86 % of the aroma-
therapy group received dexamethasone. The groups were
also compared for multimodal analgesia, including acet-
aminophen: 94 % of controls and 95 % of aromatherapy
subjects received multimodal analgesia.
For the primary outcome, 14/18 (78 %) of controls
reached the cutoff of a 2-point reduction on the BARF
scale compared to 19/21 (90 %) in the aromatherapy
group (p = 0.39, Eta 0.175) (Table 2). Other outcomes in-
cluded use of antiemetic in PACU (control 44 %, aroma-
therapy 52 % P = 0.75, Eta 0.08), emesis (Control 11 %,
9 % aromatherapy, P = 0.87, Eta = 0.03) and reduction in
BARF scale magnitude at 15-min post intervention [con-
trol 3.8 (95 % CI ±3.7), aromatherapy 3.2 (95 % CI ±2.4),
p-value = 0.52, Eta = 0.01)] (Table 2). There was a statis-
tically significant difference in whether subjects contin-
ued to use the intervention (control 28 %, aromatherapy
66 %, p-value 0.048, Eta 0.33) (Table 2). Subjects were
considered to have continued the intervention if they
used the intervention beyond the first 15 min.
Fig. 1 An example of a placebo or aromatherapy inhaler is shown above
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Study feasibility indicators
There were 46 study days over a period of 6 months
resulting in 3.2 subjects recruited per study day and a
randomization rate of 0.9 subjects per day. Approximate
cost of the study was $8 000 mainly from research assist-
ant salary and to a small extent, materials. Thus, a cost
of $205 for each randomized subject.
Discussion
The primary goal of the current study was to assess the
feasibility of a larger trial of aromatherapy for PONV in
children. The primary outcome of 2-point reduction in
the BARF scale was a surrogate for moderate PONV.
The outcome had only a small-modest effect size (con-
trol 78 %, aromatherapy 90 %, Eta = 0.175). In order to
be powered to a significance level (α) of 0.05 and power
of 0.8, the sample size would need to be approximately
514 per group (making no adjustments for attrition) using
the effect size of the primary outcome. Alternatively using
the incidence of nausea the sample size would be 190 pa-
tients per group. Given the recruitment rates of the study
the lowest estimate of number children we would need to
screen is 1 200. Concrete, less subjective outcomes such
as pharmacological intervention or emesis would require
even larger sample sizes to find any difference as evi-
denced by the low effect sizes found in this study (0.08
and 0.03 respectively).
Nausea rates at our center (27 %) were close, though
somewhat lower, to literature values [2, 6]. Compliance
with recommendations for PONV prophylaxis are con-
sistent with recommendations from major society guide-
lines [1]. Most children in this study received both
Ondansetron (74 %) and dexamethasone (95 %) as intra-
operative prophylaxis. Multimodal analgesia was utilized
in most patients to reduce narcotic use (95 %). The
widespread use of multi-modal analgesia and PONV
prophylaxis in our center likely has resulted in our lower
rates of nausea.
Fig. 2 Consort Flow Diagram
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Limitations of the study include low planned sample
size, as this was a pilot study. Unreliability of the out-
come measurement (BARF scale) in the youngest chil-
dren may also contribute to error. Although the BARF
scale has been validated down to 4 years old, there is
variability in children’s ability to self-report on internal
experiences in this age group that may have influenced
their use of this scale [11].
Despite randomization there was a difference in the
types of surgeries patients in each group received. For
example, more patients in the control group had Oph-
thalmological surgery compared with aromatherapy
(28 % versus 5 %). This was likely balanced by a higher
portion of aromatherapy patient’s having ENT surgery.
Initial nausea scores were not different between the two
groups. In future study stratification by surgery may be
necessary. Furthermore, the primary outcome measure-
ment is an indirect surrogate rather than a concrete out-
come. As PONV can occur for a period spanning longer
than the time patients spend in day surgery, this study
would not account for any PONV experienced, and
possibly prevented by the intervention, en route home
or over the first 24 h. Modifiable limitations include
better concealment. Despite a delivery system with
controlled exposure to the therapy (twist top) the
aroma rapidly penetrated the area around the patient.
Researchers and nurses correctly identified interven-
tion versus control in all cases. In future studies nose
plugs could be considered.
Future directions may include an adequately pow-
ered study with more attention to concealment and
the inclusion of less subjective outcomes (reduction
in emesis, and reduction in rescue anti-nausea medi-
cations). However, given the small effect size, the
value is dubious. Other areas to consider exploring
are the effects of aromatherapy on PONV, comfort,
anxiety and pain in the extended post-operative
period (i.e., over the following 24–48 h). Subjects in
the aromatherapy group were more likely to continue
using the intervention compared to the control group
(66 % versus 28 % p-value 0.048, Eta 0.33). This may
suggest that the aromatherapy could be having an-
other unmeasured effect on patient comfort. This ef-
fect may be a reduction in anxiety. In future studies
this should be explored further (measures of pain,
comfort or anxiety reduction for example).
Conclusion
This pilot study revealed methodological flaws that need
to be corrected before embarking on a larger random-
ized control study. A larger trial would likely need to
take place at a larger center or be multi-center in order
to speed recruitment.
Table 1 Summary of demographic data between control and
aromatherapy arm
Control Aromatherapy
Age (YEAR) 8.5 (95 % CI ±3.4) 6.9 (95 % CI ±3.1)
Sex (%male) 9/18 (50 %) 12/21 (57.1 %)
ASA (I or II) 100 % 100 %
Surgery
ENT 8/18 44 % 17/21 81 %
Ophthalmology 5/18 27.8 % 1/21 4.8 %
Plastic surgery 2/18 11.1 % 0/21 0 %
Orthopaedics 0/18 0 % 0/21 0 %
Dental 1/18 5.6 % 3/21 14.3 %
Urology 0/18 0 % 0/21 0 %
General surgery 2/18 11.1 % 0/21 0 %
OR time (minutes) 66 (95 % CI ±18) 64 (95 % CI ±34)
PONV Prophylaxis
TIVA 4/18 22 % 4/21 19 %
Ondansetron 14/18 77.8 % 15/21 71 %
Dexamethasone 17/18 94.4 % 18/21 85.7 %
Pain management
Acetaminophen 17/18 94.4 % 20/21 95.2 %
Ketorolac 6/18 33 % 2/21 9.5 %
Morphine dose (mg/kg) 0.14 (95 % CI ±0.1) 0.13 (95 % CI ±0.09)
Continuous data were expressed as mean and 95 % CI. Otherwise data
expressed as percentage of subjects meeting outcome
Table 2 Summary of primary and secondary outcomes
Control Aromatherapy p-value Effect (Eta)
2 point reduction on BARF scale (Y/N) 14/18 (77.8 %) 19/21 (90.5 %) 0.39 0.175
Use of pharmacological rescue (Y/N) 8/18 (44.4 %) 11/21 (52.4) 0.75 0.079
Emesis (Y/N) 2/18 (11.1 %) 2/21 (9.5 %) 0.87 0.026
Continued use of intervention (Y/N) 5/18 (28 %) 14/21 (66 %) 0.048 0.33
Reduction in BARF scale magnitude 3.8 (95 % CI ±3.7) 3.2 (95 % CI ±2.4) 0.52 0.01
Reduction in BARF magnitude is expressed as mean and 95 % CI. The means were compared using T-Test with calculation of effect size. Otherwise data are
expressed as percentage of subjects meeting the outcome (binary Y/N) and means were compared using Chi-Square test with calculation of effect size
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